References
- Julius S., Schork M. A. Borderline hypertension‐a critical review. J Chron Dis 1971; 23: 723–754
- Julius S., Jamerson K., Mejia A., Krause L., Schork N., Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA 1990; 264: 354–358
- Nesbitt S. D., Julius S., Leonard D., Egan B. M., Grozinski M., for the TROPHY Study Investigators. Is low‐risk hypertension fact or fiction?. Am J Hypertens 2005; 18: 980–985
- Julius S., Nesbitt S., Egan B., Kaciroti N., Schork M. A., Grozinski M., , for the TROPHY Study Group, et al. Trial of preventing hypertension. Design and 2‐year progress report. Hypertension 2004; 44: 146–151
- Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347–504
- Panza J. A., Casino P. R., Kilcoyne C. M., Quyyumi A. A. Role of endothelium‐derived nitric oxide in the abnormal endothelium‐dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468–1474
- Egan B., Panis R., Hinderliter A., Schork N., Julius S. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80: 812–817
- Hart M. N., Heistad D. D., Brody M. J. Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels. Hypertension 1980; 2: 419–428
- Dzau V. The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. J Hypertens 2005; 23(Suppl 1)S9–S17
- Esler M., Julius S., Zweifler A., Randall O., Harburg E., Gardiner H., et al. Mild high‐renin essential hypertension: Neurogenic human hypertension?. N Engl J Med 1977; 296: 405–411
- Julius S., Krause L., Schork N. J., Mejia A. D., Jones K. A., van de Ven C., et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991; 9: 77–84
- Schiffrin E. L., Deng L. Y., Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I‐converting enzyme inhibitor. Am J Hypertens 1995; 8: 229–236
- Schiffrin E. L., Deng L. Y. Comparison of effects of angiotensin I‐converting enzyme inhibition and (‐blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25: 699–703
- Harrap S. B., Van der Merwe W. M., Griffin S. A., Macpherson F., Lever A. F. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long‐term. Hypertension 1990; 16: 603–614
- Wu J. N., Berecek K. H. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993; 22: 139–146
- Qureshi A. I., Suri M. F. K., Kirmani J. F., Divani A. A. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005; 11: CR403–409
- Julius S., Nesbitt S. D., Egan B. M., Weber M. A., Michelson E. L., Kaciroti N., et al. Feasibility of treating prehypertension with an angiotensin‐receptor blocker. N Engl J Med 2006; 354: 1685–1697
- The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high‐normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657–667